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Abstract
The treatment of Alzheimer's disease (AD) with cholinesterase inhibitors (ChEIs) is 
based on the cholinergic hypothesis. This hypothesis fails to account for the global 
nature of the clinical effects of ChEIs, for the replication of these effects in other 
dementias, and for the strong and unpredictable intraindividual variation in 
response to treatment. These findings may be better explained by the premise that 
ChEIs primarily act by augmenting cerebral perfusion: the cholinergic-vascular 
hypothesis. This article will review the evidence from preclinical and clinical 
investigations on the vascular role of the cholinergic neural system. The clinical 
relevance of this hypothesis is discussed with respect to its interactions with the 
vascular and amyloid hypotheses of AD. Implications for treatment are indicated. 
Finally, we propose that the role of the cholinergic system in neurovascular 
regulation and functional hyperemia elucidates how the cholinergic deficit in AD 
contributes to the clinical and pathological features of this disease.
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The treatment of Alzheimer’s disease (AD) with cholinesterase inhibitors (ChEIs) is 
based on the cholinergic hypothesis1-3. Thirty years ago, post mortem studies 
revealed a severe loss of cholinergic innervation in brains of AD patients1,2. The 
severity of this cholinergic deficit was later found to correlate with the level of 
cognitive impairment4,5. Furthermore, it was observed that the loss of cholinergic 
innervation in AD occurs most prominently in the hippocampus and temporal 
cortex; this loss could account for the clinical presentation with a predominant and 
severe loss of memory6,7. Although the concept of a cholinergic deficit as a 
monocausal model for AD has long since been abandoned, there is solid evidence 
for the important role of the cholinergic system in the processes of memory, 
attention, and behavior6,8.
ChEIs (donepezil, galantamine, and rivastigmine) reduce the synaptic 
breakdown of acetylcholine (Ach) and thus partially correct the cholinergic deficit. 
Early expectations were that these drugs would produce a significant improvement 
in memory. In practice, however, treatment effects are far more global and consist 
of modest improvements in cognition, attention, executive function (including
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activities of daily living), and global rating scales9 . In addition, the response to 
treatment varies markedly among patients, and it is currently unpredictable 
whether an individual patient will benefit from therapy. These findings cannot be 
fully explained from the cholinergic hypothesis.
Moreover, the observed treatment effects are not specific for AD. Very similar 
outcomes can be found in patients with vascular cognitive impairment, dementia 
with Parkinson’s disease, and dementia with Lewy bodies12-15. It should be noted 
that this nonspecificity of treatment effects may in part reflect the current lack of 
precision in diagnosing and separating ‘‘pure’’ forms of AD and other dementias. In 
contrast, these data could point toward a different mode of action of ChEIs than is 
suggested by the cholinergic hypothesis. A further argument for this explanation is 
the finding that healthy individuals receiving ChEIs show increased attention and 
reaction speed and, in airline pilots, improved scores on flight simulator tasks16.
There is substantial evidence for the hypothesis that ChEIs primarily act by 
improving cerebral blood flow (CBF). We will refer to this premise as the 
cholinergic-vascular hypothesis. A cholinergic augmentation of CBF could account 
for the global nature of the observed clinical improvement. It also serves to explain 
why this benefit is not limited to AD. Finally, it may clarify the intraindividual 
variation in response to treatment. These aspects will be further addressed in this 
article. The clinical relevance of this hypothesis is found in the recent recognition 
of the importance of vascular disease in the etiology of AD, in the frequent
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occurrence of cerebrovascular comorbidity in AD, and in the growing interest in the 
use of ChEIs for the spectrum of vascular cognitive impairment.
The cholinergic-vascular hypothesis is based on the property of the brain’s 
cholinergic neurons to induce cerebral vasodilatation and to augment CBF17,18. 
These attributes of cholinergic neurons, together with the vascular effects of 
ChEIs, have been thoroughly investigated. This article will review the pertinent 
evidence for this hypothesis and discuss its implications for patient care and 
research. The classic cholinergic deficit hypothesis and the new cholinergic- 
vascular hypothesis can be mutually viable, and the interaction between these 
hypotheses will be addressed, with an additional comment on a possible 
interaction with the amyloid hypothesis.
Evidence for the cholinergic-vascular hypothesis
Cholinergic Vasodilatory Innervation of Cerebral Blood Vessels 
The basal forebrain is the major source of brain cholinergic neurons. The 
hippocampus receives most of its input from the medial septal nucleus and the 
diagonal band of Broca, whereas the whole of the cerebral cortex is supplied by 
the nucleus basalis of Meynert (NBM) 19. The most compelling evidence for the 
cholinergic-vascular hypothesis was found with the demonstration that these 
basal forebrain cholinergic neurons have projections to cerebral blood vessels. 
More precisely, in both rats and humans, arterioles in the frontoparietal cortex 
were found to contain perivascular cholinergic nerve terminals, and their origin 
could be traced back to the NBM 20,21. When brains of AD patients were compared
with those of age-matched controls, there was a loss of cholinergic innervation in
21cortical arterioles in AD, most prominently in the temporal lobes21.
The neurotransmitter for cholinergic neurons is Ach, which is also a potent 
vasodilator and can bind to two receptor types: nicotinic and muscarinic. Basal 
forebrain cholinergic neurons primarily involve muscarinic receptors. Evidence that 
Ach can induce vasodilatation as a postsynaptic neurotransmitter has come from 
the identification of these muscarinic receptors in perivascular astrocytes, smooth 
muscle cells, and endothelial cells, in cortical arterioles 22,23.
In addition to these direct connections between NBM cholinergic neurons and 
cortical blood vessels, indirect connections involving nitrergic interneurons have 
been identified 20,21,24. Cholinergic stimulation of these interneurons causes 
vasodilatation through the release of nitric oxide.
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Stimulation and Inhibition of Cholinergic Neurons Modulates Cerebral Perfusion 
Experiments in rats demonstrated that electrical and chemical stimulation of 
cholinergic neurons in the NBM results in a significant increase in CBF in several 
cortical areas25-29. It is uncertain, however, if these stimuli were truly selective to 
the NBM. Other groups of neurons may have been activated as well. In contrast, 
inhibition of cholinergic neurons can be achieved with high selectivity. Following 
complete destruction of the NBM by a cholinergic immunologic toxin (192 
immunoglobulin G-saporin), CBF decreased globally. Most severely affected 
regions included the posterior parietal and temporal regions (24%-40% decrease) 
30. It is remarkable that the regional distribution of hypoperfusion corresponded to 
the regions of the brain that are most prominently affected in AD.
The long-term effects of cholinergic inhibition were described in one study that 
found deposits of amyloid-betaprotein (ap) in the cerebral vasculature 6 months 
after a lesion to the NBM31. In patients with AD, deposits of ap are found in the 
cortex in the form of neuritic plaques, but also around cortical vessels, especially in 
patients with vascular comorbidity32,33.These data can be interpreted as follows: 
The cholinergic deficit promotes perivascular ap-deposition, which could contribute 
to chronic brain hypoperfusion. Alternatively, vascular ap-deposition may be a 
result of the chronic hypoperfusion that follows a cholinergic lesion.
Cholinergic and Anticholinergic Drugs Influence CBF
The effects of stimulation and inhibition of cholinergic neurons have also been 
assessed in pharmacological experiments. Scopolamine, an anticholinergic drug, 
blocks the binding of Ach to its muscarinic receptor. In young humans, 
scopolamine reduced frontal cerebral perfusion by 20% 34. An increase in CBF in 
various cortical regions was observed with cholinergic drugs (the ChEIs 
eptastigmine and physostigmine) in young and aged humans35. Moreover, 
physostigmine was able to restore CBF after it had been reduced by 
scopolamine36. In rats, rivastigmine reduced brain injury from hypoperfusion, 
indicating that autoregulation of CBF was improved37.
Effects of ChEI Treatment on CBF in AD
Computed tomography using radionuclides has provided information on regional 
changes in CBF in Alzheimer patients. Two early studies, looking at the effects of 
a single ChEI dose on CBF, found an increase in posterior parietotemporal and 
superior frontal perfusion38,39. The longer-term outcome of treatment with ChEIs 
has been investigated extensively40-48. Prospective studies in untreated patients
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have found a strong correlation between clinical deterioration and progressive 
regional hypoperfusion. Consistently, patients who responded to treatment 
showed either improvement or stabilization of CBF49. In contrast, nonresponders 
(those patients who demonstrated progressive cognitive deterioration with 
neuropsychological evaluation) had a progressive decline of CBF50. Aside from 
AD, a rise in CBF after treatment with ChEIs was noted in patients with vascular 
dementia, dementia with Lewy bodies, and dementia of Parkinson’s disease, albeit 
in case reports and investigations in small numbers of patients50-53.
The Increase in CBF Is Not an Effect of Increased Metabolism 
An obvious thought is that the augmentation of CBF by ChEIs is a consequence of 
a regional increase in cerebral metabolism, which in turn is caused by cholinergic 
activation of cortical neurons. The available data, however, point toward a direct 
vascular effect. Blocking cortical neuronal activity did not prevent the increase in 
blood flow induced by cholinergic agonists54. Electrical stimulation of the rat NBM 
augmented cortical CBF (up to 300% in frontal areas) without an increase in 
metabolic activity28,29. Physostigmine increased CBF in both healthy young and 
aged humans, without a rise in cerebral glucose consumption35. Other studies 
have also confirmed the lack of activation of glucose metabolism by physostigmine 
in rats and humans55,56. In AD patients receiving ChEIs, the effects on CBF, 
paralleled by clinical effects, preceded effects on glucose metabolism by 
months45,57.
Effects of CBF on Cognition
Central to the cholinergic-vascular hypothesis is the assumption that an increase 
in CBF improves cognition. To the best of our knowledge, direct evidence for this 
assumption is lacking, although the available circumstantial evidence is highly 
suggestive. In patients with carotid stenosis and impaired cerebral perfusion, 
restoration of normal cerebral perfusion by carotid endarterectomy improved 
cognitive functioning58,59. In these studies, impairment in cerebrovascular reserve 
was used as a surrogate marker for chronic cerebral hypoperfusion, and 
postoperative restoration of cerebrovascular reserve was interpreted as an 
increase in cerebral perfusion. A recent investigation, however, found no 
improvement in cognition related to carotid endarterectomy60. The cerebral 
hemodynamic status of these patients was not reported in this study. Therefore, 
an absence of cerebral hypoperfusion prior to surgery could explain the lack of 
cognitive benefit, which would be consistent with the previous investigations.
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Two brief reports have mentioned an improvement in cognition after pacemaker 
implantation in older patients with bradycardia61,62. In the first report, an 
improvement in CBF after implantation was correlated with an improvement in 
cognition. In the second report, the most striking effect on cognition was observed 
in three patients with dementia; in one of these patients, the dementia had fully 
reversed 6 months after implantation of the pacemaker.
The association between a reduced CBF and cognitive impairment has received 
much more attention. In the Rotterdam Study, a large population-based cohort 
study, individuals with cognitive decline were found to have lower CBF than were 
those individuals who had stable cognitive function in the previous years63. Others 
have found that reduced CBF correlated with reduced cognitive functioning, 
regardless of the underlying brain disease64. The mechanism for this relationship 
is likely to be the increasing sensitivity of neurons to ischemia or hypoperfusion 
with age65. The evidence for the causal relationship between impairment in CBF, 
neuronal injury, and cognitive decline has recently been reviewed elsewhere17,66.
Clinical relevance
Interaction With the Vascular, Cholinergic, and Amyloid Hypotheses of AD 
The cholinergic-vascular hypothesis implies that the cholinergic deficit in AD not 
only affects cholinergic innervation of cortical neurons, but also leads to a loss of 
cholinergic innervation of cortical blood vessels. This vascular cholinergic deficit 
causes (regional) cerebral hypoperfusion, which in turn contributes to cognitive 
decline and neurodegeneration. Consequently, treatment with ChEIs may improve 
clinical functioning by augmenting cerebral perfusion. This mechanism offers an 
explanation for the intraindividual variation in response to treatment in AD. Recent 
research has focused on the vascular risk factors and the signs of overt vascular 
disease that are observed in many patients with a d 17,66,67. Cholinergic 
augmentation can lead to an increase in CBF only if the cerebral vasculature is
able to respond with vasodilatation. The presence of severe microvascular
18deformity that is found in certain AD patients18, as well as endothelial dysfunction 
from vascular disease or ischemia68,69, could reduce or obstruct cholinergic 
vasodilatation. This obstruction would explain the lack of clinical response in a 
large subgroup of AD patients. Theoretically, these patients might benefit from the 
addition of medication aimed at improving vascular endothelial function, such as 
statins and angiotensin-converting enzyme (ACE) inhibitors.
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Vasodilatation mediated by Ach is reduced by ap, and ap increases neuronal 
susceptibility to ischemia70-72. Vice versa, ischemia promotes vascular and 
neuronalab deposition 66,73. Therapeutic interventions aimed at reducing ab burden 
are thus likely to benefit from and be synergistic with strategies to improve cerebral 
perfusion [for review, see74].
Because hypoperfusion contributes to the neuropathology of AD, the (partial) 
restoration of perfusion by ChEIs may slow neurodegeneration and hence 
progression of disease. Because there is no reason to assume that ChEIs halt 
cholinergic degeneration itself, the positive effect on CBF is likely to wane with the 
progressive loss of cholinergic neurons. Indeed, ChEI treatment stabilizes disease 
for a short period of time and may slow disease progression, but it fails to halt it, as 
has been observed in all trials in AD and, more recently, in Mild Cognitive 
Impairment9,11,75. Combining ChEI therapy with strategies aimed at reducing 
cholinergic degeneration may hold promise to slow disease progression76,77.
Neurovascular Regulation
The original cholinergic hypothesis and the new cholinergic-vascular hypothesis 
are not mutually exclusive. In contrast, they can coexist if we attribute a dual role 
to the cholinergic system: the coordination of neuronal activation and perfusion in 
cognitive tasks. This review has provided evidence that the cholinergic system is 
equipped to increase regional cerebral perfusion. Recent other reviews6,78 have 
summarized the large volume of evidence that this system also controls cognitive 
and attentional processes. Most experiments on this topic suggest that it acts as a 
central control system that shifts activity between cortical areas and regulates the 
process of attention, a prerequisite to perform cognitive tasks. Studies that explore 
patterns of cognitive activation use changes in cerebral hemodynamics as a 
surrogate measure for neuronal activity. For instance, functional magnetic 
resonance imaging (fMRI) measures the blood oxygen level dependent (or BOLD) 
signal, which depends on changes in deoxyhemoglobin. This practice is valid 
because changes in blood oxygenation occur almost instantaneously with 
neuronal activation79. The striking temporal and spatial association of neuronal 
activation and increased blood flow fuels a speculative hypothesis on the 
physiological role of the cholinergic system. This system has the unique capability 
to activate regional cortical neurons through its cortical projections from the NBM 
and, at the same time, to direct blood flow to these neurons by simultaneously 
dilating the corresponding cortical microvessels through its vascular projections 
from that same NBM. This mechanism ensures that adequate nutrients (oxygen
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and glucose) are directly available for activated neurons. This process of coupling 
of CBF with neuronal activation is described as functional hyperemia. Even though 
this mechanism is more complex than is suggested here, it is not unthinkable that 
the cholinergic system has a part in it. In AD, the cholinergic deficit will impair 
neurovascular regulation and lead to neuronal dysfunction and cognitive decline. 
Cerebrovascular disease and ap deposition further contribute to this uncoupling by 
delaying the hemodynamic response following neuronal activation73,74,80.
Future research
The validity and clinical relevance of this hypothesis need further confirmation in 
future studies. More precisely, such research could investigate whether 
nonresponders (AD patients who do not benefit from ChEIs) have an impaired 
vasodilatory response to ChEIs in comparison with responders. If so, a next step is 
to evaluate whether adding vascular therapy can improve this response. Recent 
developments in monitoring cerebral hemodynamics, such as fMRI, transcranial 
Doppler sonography, and near infrared spectroscopy, facilitate the noninvasive 
registration of the vascular effects of cholinergic augmentation in patients with 
dementia. For instance, transcranial Doppler sonography measures changes in 
CBF velocity, and near infrared spectroscopy measures changes in cerebral 
cortical tissue oxygenation, both with excellent temporal resolution and a relatively 
low cost. Both high temporalands patial resolutions for measuring CBF and brain 
tissue oxygenation are offered by fMRI81. Specifically, arterial spin labeling 
techniques allow dynamic monitoring of changes in regional CBF, whereas 
diffusion tensor imaging may identify subtle changes in white matter integrity, 
which could be used as sensitive outcome parameters to record the effects of 
vascular treatment82.
Regarding the concept of neurovascular regulation, it can be hypothesized that 
ChEIs will augment functional hyperemia in AD. If such an effect can indeed be 
observed, for instance with fMRI or positron emission tomography using a cortical 
stimulation paradigm, this may prove a valuable parameter to measure the 
complex response to pharmacotherapy in AD.
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